Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - ViroPharma Incorporated (NasdaqNM:VPHM)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
405 Eagleview Boulevard
Exton, PA 19341
Phone: (610) 458-7300
Fax: (610) 458-7380
Email: investor@viropharma.com
Employees (last reported count): 149
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 41%
·Institutional: 78% (132% of float)
(119 institutions)
·Net Inst. Buying: 5.72M shares (+28.23%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
ViroPharma Incorporated is a pharmaceutical company dedicated to the commercialization, development and discovery of new antiviral medicines. The Company has focused its current product development and discovery activities on a number of ribonucleic acid, or RNA, virus diseases. These include viral respiratory infection (VRI), often referred to as the common cold; hepatitis C; and respiratory syncytial virus disease, or RSV disease. The Company currently is developing its most advanced product candidate, Picovir (pleconaril), for the treatment of common diseases caused by picornaviruses. In preclinical studies, Picovir has been demonstrated to inhibit picornavirus replication in vitro by a novel, virus- specific mode of action. Picovir works by inhibiting the function of the viral protein coat, also known as the viral capsid, which is essential for virus infectivity and transmission.
More from Market Guide: Expanded Business Description

Financial Summary
VPHM is engaged in the discovery and development of proprietary antiviral pharmaceuticals for the treatment of diseases caused by RNA viruses. For the six months ended 6/30/01, revenues increased 67% to $2.5 million. Net loss applicable to Common totaled $41.1 million, up from $12.5 million. Revenues reflect the completion of two large phase three clinical trials with Picovir. Net loss reflects costs related to the expansion of intellectual property rights of Picovir.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Claude Nash, Ph.D., 58
Chairman
$622K$311.6K
Michel De Rosen, 50
Pres, CEO, Director
1.6M--  
Vincent Milano, 37
CFO, VP, Treasurer
351K166.8K
Thomas Doyle, 40
VP, Gen. Counsel and Sec.
327K7.0K
Marc Collett, Ph.D., 49
VP of Discovery Research
417K58.4K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VPHMAs of 31-Aug-2001
Price and Volume
52-Week Low
on 9-Jan-2001
$12.75 
Recent Price$31.05 
52-Week High
on 19-Apr-2001
$41.00 
Beta0.39 
Daily Volume (3-month avg)144.3K
Daily Volume (10-day avg)194.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change+13.9%
52-Week Change
relative to S&P500
+52.9%
Share-Related Items
Market Capitalization$580.5M
Shares Outstanding18.7M
Float11.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.01 
Earnings (ttm)-$4.50 
Earnings (mrq)-$0.67 
Sales (ttm)$0.19 
Cash (mrq)$9.58 
Valuation Ratios
Price/Book (mrq)5575.86 
Price/EarningsN/A 
Price/Sales (ttm)165.38 
Income Statements
Sales (ttm)$3.00M
EBITDA (ttm)-$71.0M
Income available to common (ttm)-$71.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-32.24%
Return on Equity (ttm)-304.46%
Financial Strength
Current Ratio (mrq)15.18 
Debt/Equity (mrq)1,734.86 
Total Cash (mrq)$179.0M
Short Interest
As of 8-Aug-2001
Shares Short2.56M
Percent of Float23.3%
Shares Short
(Prior Month)
2.43M
Short Ratio19.88 
Daily Volume129.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.